Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

for
Triple Negative Breast Cancer, Residual Disease
Location: Lebanon NH, New York NY
Sponsor: Dartmouth-Hitchcock Medical Center

Sex: All

Age: 18 - 70+

Code: NCT06134375

Phase 1, Phase 2, Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

for
Non Small Cell Lung Cancer, Triple Negative Breast Cancer,
Location: Boston MA, Buffalo NY, Orlando FL, Sarasota FL,
Sponsor: Compass Therapeutics

Sex: All

Age: 18+

Code: NCT06150664

Phase 1, Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for
Triple-Negative Breast Cancer
Location: Halifax, Moncton, Rimouski, Farmington CT, New Haven CT,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06393374

Phase 3, Recruiting

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

for
Ovarian Neoplasms, Endometrial Neoplasms,
Location: Mineola NY, New York NY, Columbus OH, Atlanta GA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06400472

Phase 1, Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

for
Carcinoma, Non-Small-Cell Lung,
Location: Montreal, Fairfax VA, Toronto, Cleveland OH, Detroit MI,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All

Age: 18+

Code: NCT05208762

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

for
Triple Negative Breast Cancer
Location: Canton OH, Columbus GA, Springfield MO
Sponsor: Jina Pharmaceuticals Inc.

Sex: Female

Age: 18 - 65

Code: NCT03671044

Phase 3, Recruiting

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

for
Non-Small-Cell Lung Carcinoma, Malignant Melanoma,
Location: Elizabethtown KY
Sponsor: VastBiome

Sex: All

Age: 18+

Code: NCT05037825

Recruiting

A Multicenter Cancer Biospecimen Collection Study

for
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell,
Location: San Francisco CA
Sponsor: Cofactor Genomics, Inc.

Sex: All

Age: 18+

Code: NCT04510129

Recruiting

Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

for
Triple-negative Breast Cancer
Location: El Paso TX
Sponsor: Texas Tech University Health Sciences Center, El Paso

Sex: Female

Age: 18 - 70+

Code: NCT04362462

Recruiting

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

for
Triple Negative Breast Cancer
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: Female

Age: 18+

Code: NCT06245889

Phase 2, Recruiting

Tier Palliative Care For Patients With Advanced Heart Failure or Cancer

for
Advanced Heart Failure,
Location: Astoria NY, New York NY
Sponsor: Icahn School of Medicine at Mount Sinai

Sex: All

Age: 18+

Code: NCT07391956

Recruiting

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

for
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma,
Location: Montreal, Ottawa, Toronto, Calgary
Sponsor: Canadian Cancer Trials Group

Sex: All

Age: 15+

Code: NCT07297667

Phase 1, Recruiting

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

for
Triple Negative Breast Cancer
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: Female

Age: 18+

Code: NCT05989828

Phase 1, Recruiting

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

for
Esophageal Squamous Cell Carcinoma,
Location: New Haven CT, Lake Success NY, New York NY,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07503808

Phase 1, Recruiting

Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC

for
Aerobic Exercise, Early Stage Triple Negative Breast Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07216495

Recruiting

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

for
Triple Negative Breast Cancer
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: Female

Age: 18 - 70+

Code: NCT04861077

Early Phase 1, Recruiting

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

for
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer,
Location: Lebanon NH, Atlanta GA, Milwaukee WI, Honolulu HI
Sponsor: OncoTherapy Science, Inc.

Sex: All

Age: 18+

Code: NCT02926690

Phase 1, Recruiting

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

for
Triple Negative Breast Cancer
Location: New Haven CT
Sponsor: Yale University

Sex: Female

Age: 18+

Code: NCT07066189

Recruiting

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

for
Multiple Myeloma, Triple Negative Breast Cancer,
Location: Boston MA
Sponsor: Andrew Hantel, MD

Sex: All

Age: 18+

Code: NCT07341867

Phase 1, Recruiting

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

for
Triple Negative Breast Cancer
Location: Pittsburgh PA
Sponsor: University of Pittsburgh

Sex: Female

Age: 18+

Code: NCT07332975

Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial